Why a Random Growth Hormone Blood Test Tells You So Little: Pulsatility and Stimulation Testing Explained

Growth hormone is released in short pulses and cleared within minutes, so a single blood draw captures an arbitrary moment rather than a person's true status. This article explains why clinicians rely on IGF-1 and, where indicated, dynamic stimulation testing instead.

By UAE Peptide Clinic Research Desk

It is a natural assumption that if you want to know about your growth hormone, you should simply measure it. Many patients ask why a standard panel does not include a plain growth hormone (GH) level, or why one that was run came back low, high or unremarkable without telling anyone much. The answer lies in how the hormone behaves in the body, and understanding it explains why physician-led protocols are built around other markers.

GH is released in pulses, not at a steady level

The pituitary gland does not release growth hormone continuously. Research on the GH axis describes a pulsatile pattern: brief bursts of secretion separated by long periods in which the circulating level is very low, often close to undetectable on standard assays. The largest pulses tend to occur shortly after the onset of deep sleep, with smaller pulses through the day that are influenced by exercise, fasting, stress and body composition.

Once released, GH has a short half-life, generally estimated at around 15 to 20 minutes in circulation. A sample drawn at 9am on a fasting morning may therefore land in a trough in one person and on the tail of a pulse in another. Neither result says much about how much GH the pituitary produces over 24 hours.

A single growth hormone reading is a snapshot of one moment in a rhythm, not a measure of the rhythm itself.

Why IGF-1 is usually measured instead

Much of GH's activity is mediated through insulin-like growth factor 1 (IGF-1), which is produced mainly by the liver in response to GH. Because IGF-1 is bound to carrier proteins and cleared slowly, its level is far more stable across the day. Research suggests it works as a rough integrated marker of GH exposure over recent weeks.

That stability is why IGF-1 is the usual baseline and monitoring marker in GH-axis work. It has limits of its own, and results are interpreted against age- and sex-specific reference ranges alongside factors such as:

• Nutritional status, including very low calorie or low protein intake, which can suppress IGF-1 despite normal GH secretion
• Liver function, since the liver is the main source of circulating IGF-1
• Thyroid status, poorly controlled diabetes and recent illness, all of which can shift the result
• Oral oestrogen, which is known to lower IGF-1 independently of pituitary output

Where dynamic stimulation testing fits

When a clinician needs to assess whether the pituitary can mount a GH response at all, for example when adult GH deficiency is suspected because of pituitary disease, the accepted approach is a dynamic test rather than a random draw. These protocols give a stimulus, such as insulin-induced hypoglycaemia, glucagon or the oral GH secretagogue macimorelin, and then take timed blood samples to see whether GH peaks above a defined cut-off.

These tests are carried out in endocrinology settings, often with monitoring, because some stimuli carry real risk. They address a specific diagnostic question and are not a routine part of a wellness or longevity workup. Results also vary by assay, body mass index and the test used, so interpretation belongs with an endocrinologist.

What this means for peptide protocols

GH-axis peptides such as the secretagogues and growth hormone releasing hormone analogues are studied for their effect on endogenous pulses, which is another reason a single post-dose GH value is hard to interpret. A reading depends on how long after administration the sample was taken, the time of day and the person's sleep and meal pattern.

In practice, a careful clinic builds the picture from several sources: a baseline IGF-1 with the metabolic, liver, thyroid and glucose markers that influence it, a full medical history, symptoms tracked over time, and repeat IGF-1 testing at agreed intervals. Any change in that picture is read in context, with the understanding that preclinical and early clinical data on these compounds are still developing.

If you're exploring GH-axis testing as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.